NRSN Company Profile and Key Details

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) closed at $0.35 USD, gaining $0.02 (4.58%) from the previous close of $0.33. The stock is currently mid-range between its 52-week high and low $0.25 and $1.33. With a market capitalization of about $12.27 million, NeuroSense Therapeutics Ltd. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.58). Key stats such as the average daily volume over the past year has been around 359.20 thousand shares, volume is running light vs its 52-week average. Headquartered in Herzliya, TA, NeuroSense Therapeutics Ltd. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Alon Ben-Noon, the company employs approximately 17 people and listed since December 09, 2021. NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions.

NeuroSense Therapeutics Ltd. has 37.77 million shares outstanding. The public float is 23.87 million shares, elevated short interest at 1.85% of float. This equals 548.05 thousand shares. The short ratio is 1.97 days. Institutional investors hold 1.42% of the float. Insiders own 32.3%. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

NRSN has shown mixed momentum, losing -0.97% over the past week and -14.29% over the past quarter, though year-to-date performance is up 32.64%. Short-term trend indicators are mixed aligned (SMA20 -3.22%, SMA50 -0.84%, SMA200 -30.26%). The stock’s 14-day RSI is 47.64 (neutral), while the ATR of 0.08 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -65.32% below its high and over 32.6% above its low. Average 10-day trading volume of 954.13 thousand shares is significantly above the 3-month average of 298.60 thousand, indicating heightened recent market interest.

NeuroSense Therapeutics Ltd. generated EPS of -$0.58 over the past year. Five-year average earnings growth is 2.71%. Wall Street analysts project EPS growth of 28.41% annually over the next five years. The latest quarter delivered EPS of -$0.20. The next quarter is forecast at -$0.10. Next year's EPS is expected at -$0.61. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 7 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $14.00 to $3.00. The high target offers 3900.0% upside. The low target suggests 757.14% downside. The mean target is $12.43. This offers 3451.43% upside. NeuroSense Therapeutics Ltd. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended June 30, 2026, missed forecasts by 0.0%. The prior quarter beat by 210.73%. Over the last six quarters, Apple has recorded several small beats. These include -58.36% in August 01, 2025.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

NeuroSense Therapeutics Ltd. trades at a P/E ratio of -0.74, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -5.41 indicating negative book value, which may reflect financial stress. The P/FCF stands at -3.17, also below market averages.

Our AI price prediction model suggests that NeuroSense Therapeutics Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -10.71%, with price expected at $0.31 by September 25, 2026, within a range of $0.26 to $0.36 3-Month Outlook: Projected rise of 29.61%, reaching $0.45 by December 09, 2026, with a range of $0.38 to $0.51. 1-Year Outlook: Projected gain of 104.49%, with price at $0.71 by September 10, 2027, within a range of $0.00 to $0.00.

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) shares are up 32.64% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows NeuroSense Therapeutics Ltd. trading at a premium to the broader market with a P/E of -0.74. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $12.25, suggesting 3428.23% upside. Our AI forecast model points to short-term weakness (-10.71% over two weeks), a medium-term rise (29.61% over three months), and a longer-term gain (104.49% over one year), with expected trading ranges indicating moderate volatility.